B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

GABRA1

MOLECULAR TARGET

gamma-aminobutyric acid type A receptor subunit alpha1

UniProt: P14867NCBI Gene: 255414 compounds

GABRA1 (gamma-aminobutyric acid type A receptor subunit alpha1) is targeted by 14 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting GABRA1

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1gamma-Aminobutyric Acid3.5333
2Pregnanolone2.208
3Bicuculline1.614
4Etomidate Imidazole derivative anesthetic and hypnotic with little effect on blood gases, ventilation, or1.614
5Apigenin 5,7,4'-trihydroxy-flavone,1.102
6chrysin1.102
7Androsterone1.102
8Dasatinib1.102
9Ciprofloxacin0.691
10Eszopiclone0.691
11Etiocholanolone0.691
12Ondansetron0.691
13N-pyridazin-3-yl-4-(3-((5-(trifluoromethyl)pyridin-2-yl)oxy)benzylidene)piperidine-1-carboxamide [Supplementary Concept]0.691
14Triiodothyronine0.691

About GABRA1 as a Drug Target

GABRA1 (gamma-aminobutyric acid type A receptor subunit alpha1) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 14 compounds with documented GABRA1 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

GABRA1 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.